BE1007420A3 - Ampoules et solution de perfusion d'acides thioctique sous forme de sels solubles dans l'eau d'acide thioctique. - Google Patents

Ampoules et solution de perfusion d'acides thioctique sous forme de sels solubles dans l'eau d'acide thioctique. Download PDF

Info

Publication number: BE1007420A3
Authority: BE; Belgium
Prior art keywords: thioctic acid; thioctic; solution; acid; water
Prior art date: 1992-10-15

Application number

BE9300910A

Other languages

English (en)

French (fr)

Inventor

Helmut Hettche

Juergen Engel

Reinhard Muckenschnabel

Heinz Ulrich

Original Assignee

Asta Medica Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-10-15

Filing date

1993-09-03

Publication date

1995-06-13

1993-09-03 Application filed by Asta Medica Ag filed Critical Asta Medica Ag

1995-06-13 Application granted granted Critical

1995-06-13 Publication of BE1007420A3 publication Critical patent/BE1007420A3/fr

Links

150000003839 salts Chemical class 0.000 title claims abstract description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 9
238000001802 infusion Methods 0.000 title description 6
239000002253 acid Substances 0.000 title description 4
AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims abstract description 45
AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 44
235000019136 lipoic acid Nutrition 0.000 claims abstract description 44
229960002663 thioctic acid Drugs 0.000 claims abstract description 44
239000003978 infusion fluid Substances 0.000 claims abstract description 11
239000003814 drug Substances 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 3
239000000243 solution Substances 0.000 abstract description 32
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 34
229910052757 nitrogen Inorganic materials 0.000 description 17
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000008215 water for injection Substances 0.000 description 8
230000005587 bubbling Effects 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000000725 suspension Substances 0.000 description 6
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 5
239000012895 dilution Substances 0.000 description 5
238000010790 dilution Methods 0.000 description 5
XZUAPPXGIFNDRA-UHFFFAOYSA-N ethane-1,2-diamine;hydrate Chemical compound O.NCCN XZUAPPXGIFNDRA-UHFFFAOYSA-N 0.000 description 5
238000009826 distribution Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000011148 porous material Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000011109 contamination Methods 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
230000008014 freezing Effects 0.000 description 2
238000007710 freezing Methods 0.000 description 2
VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 2
238000010926 purge Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
208000003130 Alcoholic Neuropathy Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010028520 Mycotoxicosis Diseases 0.000 description 1
231100000006 Mycotoxicosis Toxicity 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
125000005263 alkylenediamine group Chemical group 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
239000005515 coenzyme Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
230000007547 defect Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
235000010299 hexamethylene tetramine Nutrition 0.000 description 1
239000004312 hexamethylene tetramine Substances 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
238000000034 method Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
ZYTYOUNYLKOKAR-UHFFFAOYSA-N morpholine;pyrrolidine Chemical compound C1CCNC1.C1COCCN1 ZYTYOUNYLKOKAR-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000005895 oxidative decarboxylation reaction Methods 0.000 description 1
125000005429 oxyalkyl group Chemical group 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BE9300910A 1992-10-15 1993-09-03 Ampoules et solution de perfusion d'acides thioctique sous forme de sels solubles dans l'eau d'acide thioctique. BE1007420A3 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE9213914U DE9213914U1 (de)	1992-10-15	1992-10-15	Ampulle und Infusionslösung von Thioctsäure in Form der wasserlöslichen Salze der Thioctsäure

Publications (1)

Publication Number	Publication Date
BE1007420A3 true BE1007420A3 (fr)	1995-06-13

Family

ID=6884846

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE9300910A BE1007420A3 (fr)	1992-10-15	1993-09-03	Ampoules et solution de perfusion d'acides thioctique sous forme de sels solubles dans l'eau d'acide thioctique.

Country Status (7)

Country	Link
BE (1)	BE1007420A3 (it)
DE (1)	DE9213914U1 (it)
ES (1)	ES2063713B1 (it)
FR (1)	FR2696933B3 (it)
IT (1)	IT1260996B (it)
NL (1)	NL9301781A (it)
PT (1)	PT101388B (it)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4433764A1 (de) *	1994-09-22	1996-03-28	Asta Medica Ag	Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE29506604U1 (de) *	1995-04-25	1995-06-14	Asta Medica Ag, 01277 Dresden	Fertiginfusionsset
ITMI20111975A1 (it) *	2011-10-28	2013-04-29	Labomar S R L	Composizioni comprendenti un sale di un acido organico.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS3814940B1 (it) *	1961-03-04	1963-08-15
JPS3922715B1 (it) *	1962-03-29	1964-10-13
JPS4526516B1 (it) *	1968-07-08	1970-09-01
EP0318891A1 (de) *	1987-12-04	1989-06-07	ASTA Medica Aktiengesellschaft	Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren
EP0427247A2 (de) *	1989-11-09	1991-05-15	ASTA Medica Aktiengesellschaft	Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1095991B (de) *	1959-05-09	1960-12-29	Chemiewerk Homburg Zweignieder	Verfahren zur Herstellung einer stabilen und injizierbaren 1,2-Dithia-cyclopentan-3-valeriansaeure enthaltenden Loesung
DE1668887B2 (de) *	1968-03-15	1976-06-16		Ca-salz der 1,2 -dithia-cyclopentan - 3- valerian saeure gleich (thioctsaeure)
JPS6066955A (ja) *	1983-09-19	1985-04-17	Kiyaraban:Kk	ドレッシングの製造方法
IT1213141B (it) *	1984-02-17	1989-12-14	Dobrivoje Tomic	Composizioni farmaceutiche per il trattamento del diabete e di malattie e disfunzioni epatiche.
DE3512911A1 (de) *	1985-04-11	1986-10-16	Degussa Ag, 6000 Frankfurt	Verfahren zur herstellung von 1,2-dithiolan-3-pentansaeure (thioctsaeure)
SE508601C2 (sv) *	1989-11-09	1998-10-19	Asta Medica Ag	Läkemedel, vilka som aktiv substans innehåller karboxylsyror innehållande svavel samt deras användning för bekämpning av retrovirus

1992
- 1992-10-15 DE DE9213914U patent/DE9213914U1/de not_active Expired - Lifetime
1993
- 1993-09-03 BE BE9300910A patent/BE1007420A3/fr not_active IP Right Cessation
- 1993-09-16 FR FR9311052A patent/FR2696933B3/fr not_active Expired - Lifetime
- 1993-10-14 NL NL9301781A patent/NL9301781A/nl active Search and Examination
- 1993-10-14 ES ES09302159A patent/ES2063713B1/es not_active Expired - Fee Related
- 1993-10-14 PT PT101388A patent/PT101388B/pt not_active IP Right Cessation
- 1993-10-15 IT ITTO930761A patent/IT1260996B/it active IP Right Grant

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS3814940B1 (it) *	1961-03-04	1963-08-15
JPS3922715B1 (it) *	1962-03-29	1964-10-13
JPS4526516B1 (it) *	1968-07-08	1970-09-01
EP0318891A1 (de) *	1987-12-04	1989-06-07	ASTA Medica Aktiengesellschaft	Injizierbare Lösung des Thioctsäuresalzes mit Trometamol und/oder basischen Aminosäuren
EP0427247A2 (de) *	1989-11-09	1991-05-15	ASTA Medica Aktiengesellschaft	Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 6800, Derwent World Patents Index; AN 66-08932F (00) *
DATABASE WPI Week 6800, Derwent World Patents Index; AN 66-14295F (00) *
DATABASE WPI Week 7034, Derwent World Patents Index; AN 70-61064R (34) *

Also Published As

Publication number	Publication date
ITTO930761A0 (it)	1993-10-15
NL9301781A (nl)	1994-05-02
PT101388A (pt)	1994-09-30
IT1260996B (it)	1996-04-29
FR2696933A3 (fr)	1994-04-22
PT101388B (pt)	1999-09-30
ES2063713A1 (es)	1995-01-01
DE9213914U1 (de)	1992-12-03
FR2696933B3 (fr)	1994-09-23
ITTO930761A1 (it)	1995-04-15
ES2063713B1 (es)	1995-07-16

Legal Events

Date

Code

Title

Description

2013-09-30

RE20

Patent expired

Owner name: *MEDA PHARMA G.M.B.H. & CO. K.G.

Effective date: 20130903

Publication	Publication Date	Title
US5589491A (en)	1996-12-31	Injection and injection kit containing omeprazole and its analogs
FR2547727A1 (fr)	1984-12-28	Compositions pharmaceutiques
CA1188989A (en)	1985-06-18	Nonapeptide for the treatment of drug withdrawal symptoms
PT1054665E (pt)	2002-02-28	Composicao farmaceutica compreendendo uma combinacao de metformina e fibrato e seu uso no tratamento da hiperglicemia
UA72268C2 (uk)	2005-02-15	Водна композиція моксифлоксацину, що містить хлорид натрію
KR20120044309A (ko)	2012-05-07	적어도 하나의 아드레날린성 화합물을 포함하는 안정화된 조성물
NZ538255A (en)	2006-11-30	Aqueous 2,6-diisopropylphenol pharmaceutical compositions
Cooke et al.	1976	Effect of first part of duodenum on gastric emptying in dogs: response to acid, fat, glucose, and neural blockade
US20250090622A1 (en)	2025-03-20	Angiotensin compositions and methods related thereto
MX2007013583A (es)	2008-03-13	Metodos y composiciones para tratar el dolor.
RU2157687C2 (ru)	2000-10-20	Фармацевтические составы для парентерального введения, содержащие n-{4-[2-(1,2,3,4-тетрагидро-6,7-диметокси-2-изохинолинил)-этил]-фенил]-9,1 0-дигидро-5-метокси-9-оксо-4-акридинкарбоксамид
BE1007420A3 (fr)	1995-06-13	Ampoules et solution de perfusion d'acides thioctique sous forme de sels solubles dans l'eau d'acide thioctique.
JPS61502821A (ja)	1986-12-04	薬物キットまたは薬物組成物
US11147926B2 (en)	2021-10-19	Intrathecal baclofen pharmaceutical dosage forms and related delivery system
JP3720262B2 (ja)	2005-11-24	安定化したカルベジロール注射溶液
FR2686513A1 (fr)	1993-07-30	Compositions pharmaceutiques aqueuses de cromoglycate sodique.
Davey et al.	1965	Pharmacology of the antihypertensive guanoxan
US4263283A (en)	1981-04-21	Method for prophylaxis and/or treatment of sickle cell disease
US4289783A (en)	1981-09-15	Etomidate-containing compositions
US20020132815A1 (en)	2002-09-19	Anti-hypertensive composition and methods of treatment
TWI316403B (en)	2009-11-01	Glycyrrhizin containing pharmaceutical composition
WO1997024125A2 (fr)	1997-07-10	Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol
US4973591A (en)	1990-11-27	Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl)piperazine
PT96003B (pt)	1998-01-30	Processo para a preparacao de composicoes farmaceuticas, contendo um derivado triazol
JPH044300B2 (it)	1992-01-27